Endometrial cancer
  • 30 Nov 2023
  • 1 Minute to read
  • PDF

Endometrial cancer

  • PDF

Article summary

In women with an intact uterus, unopposed systemic oestrogen therapy increases the risk of endometrial cancer and is not recommenced. This risk is largely avoided through a systemic progestogen.


NICE says that evidence shows a reduced risk of endometrial cancer in:

  • Current users of continuous combined HRT, with any duration of use.
  • Current users of all combined HRT with less than 5 years of use.

  • Long-term use of sequential combined regimes for >5 years may be associated with a small increase in risk of endometrial cancer.
  • Use of low dose vaginal oestrogen treatments does not increase the risk of endometrial cancer.
NOTE:
  • Continuous combined HRT, where the progestogen is taken every day with oestrogen, decreases the risk of endometrial cancer.
References and Further Information:

Was this article helpful?

What's Next